# Synthesis and Antifungal and Insecticidal Activities of NovelN-Phenylbenzamide Derivatives Bearing a Trifluoromethylpyrimidine Moiety

Authors: Xuetong Yu; Wenjun Lan; Meihang Chen; Su Xu; Xiaoxi Luo; Shuhong He; Haijiang Chen; Qiang Fei; Wenneng Wu
Journal: Journal of Chemistry
 (2021)

---

## Abstract

Seventeen novelN-phenylbenzamide derivatives bearing a trifluoromethylpyrimidine moiety were synthesized via four-step reactions. Their antifungal and insecticidal properties were evaluated. Antifungal test results demonstrated that some of the synthesized compounds showed better in vitro bioactivities against Phomopsis sp., Botryosphaeria dothidea (B. dothidea), and Botrytis cinerea (B. cinerea) at 50 μg/mL than pyrimethanil. Unfortunately, the synthesized compounds revealed lower insecticidal activities against Spodoptera frugiperda (S. frugiperda) and Mythimna separata (M. separata) at 500 μg/mL than chlorantraniliprole.


---

## Body

## 1. Introduction

Plant fungal diseases and insect pests have drawn widespread attention because of their enormous damage toward agriculture [14]. The traditional commercial fungicides and insecticides used to prevent and control plant diseases could increase the yield, improve the quality of agricultural products, and also not reduced huge loss annually [5, 6]. However, the misuse of traditional fungicides and insecticides had speeded up the resistance of plant diseases, which is rapidly becoming a huge challenge in agriculture [7, 8]. Therefore, it is still an urgent and meaningful task to develop the novel, highly efficient, and promising pesticides.Pyrimidine is one of best important chemical scaffolds for application in pesticide chemistry, medicinal chemistry, and material chemistry. Many of pyrimidine derivatives play an important role of bioactive compounds, such as antifungal [9, 10], antibacterial [11, 12], acaricidal [13, 14] insecticidal [15, 16], herbicidal [17, 18], and antiviral [19, 20] activities. Meanwhile, N-phenylbenzamide, a key active fragment in pesticide chemistry, is usually used as a pesticide active fragment and exhibit extensive biological activities, such as antiviral, antifungal, antibacterial, herbicidal, and insecticidal activities [21]. Our early work has reported a series of novel benzamide derivatives containing a pyrimidine moiety (Figure 1) with better antiviral, insecticidal, antifungal, and antibacterial activities [26–33].Figure 1
The structures of the pyrimidine derivatives reported in our previous work.Herein, to develop new highly bioactivity lead compounds, we replace benzamide toN-phenylbenzamide (Figure 2) to design a series of novel N-phenylbenzamide derivatives containing a trifluoromethylpyrimidine moiety and then evaluate their antifungal and insecticidal activities.Figure 2
Design route of the target compounds4a–4q.


## 2. Experimental

### 2.1. Materials and Methods

The melting points were obtained by using an XT-4 binocular microscope (Beijing Tech. Instrument Co., China). NMR spectral recorded on a Bruker Avance NEO 600 NMR spectrometer (Bruker Corporation, MA, USA) using DMSO-d6 as an solvent. HRMS data were obtained on a Thermo Scientific Q Exactive Fucus instrument (Thermo Fisher Scientific, CA, USA). Analytical TLC was performed on silica gel GF254.


### 2.2. General Procedure for the Preparation of Intermediates 1 and 2

Trifluoroacetoacetate (0.1 mol) with ethanol (200 mL) was added to a 500 mL round bottom flask. Then, formamidine hydrochloride (0.1 mol) or acetamidine hydrochloride (0.1 mol) and 1,8-diazabicyclo[5.4.0]undecane-7-ene (DBU, 0.15 mol) were added to the mixture and reacted for 10 h at reflux temperature. After completion, the mixture was cooled to room temperature, acidified with 1 mol/L HCl to pH 7, extracted with ethyl acetate, and evaporated under vacuum to produce intermediate 1. Then, intermediate 1 (0.1 mol), POCl3 (0.2 mol), and CH3CN (240 mL) were added to a 500 mL round bottom flask and reacted for 0.5 h at reflux temperature. After that, diisopropylethylamine (0.12 mol) was added dropwise and continuously reacted for 8 h. After completion, excess POCl3 and CH3CN were removed by distillation, and then ice-water mixture (120 mL) was added. Finally, the mixture was alkalified with 5 mol/L NaOH to pH 9 and extracted using CH2Cl2 to give intermediate 2.


### 2.3. General Procedure for the Preparation of the Key Intermediate 3

To a 100 mL round bottom flask, intermediate 2 (0.012 mol) dissolved in acetone (10 mL), Cs2CO3 (0.02 mol), and 4-hydroxybenzoic acid (0.01 mol) were added and reacted for 2-3 h at room temperature. After the completion of reaction, the excess solvent was removed, and the residue was added to distilled water (50 mL) and acidified with concentrated HCl to pH 2-3. The precipitate was filtered and recrystallized from ethanol to give key intermediate 3. The structures of intermediate 3 were confirmed by 1H NMR and 13C NMR. The physical characteristics and 1H NMR and 13C NMR data for intermediate 3 are shown as follows.


#### 2.3.1. 4-((6-(Trifluoromethyl)pyrimidine-4-yl)oxy)benzoic acid (3a)

White solid; yield: 80.1%; m.p. 147-148°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 9.02 (s, 1H, pyrimidine-H), 8.41 (s, 1H, pyrimidine-H), 8.21 (d, 1H, J = 8.4 Hz, Ph-H), 7.86 (d, J = 8.4 Hz, 1H, Ph-H), 7.70 (t, J = 7.2 Hz, 1H, Ph-H), 7.70 (t, J = 7.8 Hz, 1H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.34, 159.75, 156.12(q, J = 36.0 Hz), 143.24, 129.97, 128.63, 126.01, 121.53 (q, J = 272.85 Hz), 120.46, 109.99, 105.44.


#### 2.3.2. 4-((2-Methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzoic acid (3b)

White solid; yield: 70.0%; m.p. 145-146°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 12.56 (s, 1H, COOH), 7.80 (d, J = 8.4 Hz, 2H, Ph-H), 7.48 (s, 1H, pyrimidine-H), 6.83 (d, J = 8.4 Hz, 2H, Ph-H), 2.35 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 167.63, 162.69, 162.06, 151.96 (q, J = 35.25 Hz), 131.98, 122.09 (q, J = 273.00 Hz), 121.82, 115.56, 111.07, 25.90.


### 2.4. General Procedure for the Preparation of the Target Compounds (4a–4q)

To a 50 mL round bottom flask, the key intermediate 3 (0.024 mol), dichloromethane (20 mL), aromatic amides (0.02 mol), dimethylaminopyridine (DMAP, 0.0004 mol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 0.03 mol) were added, respectively. The reaction was carried out at room temperature for 8–10 h. After the completion of the reaction, the solvent was evaporated under vacuum condition and then the residue was recrystallized from ethanol to give pure target compounds4a–4q. The physical characteristics, 1H NMR, 13C NMR, and HRMS data for all the target compounds are shown in Supplementary Materials.


#### 2.4.1.N-(4-fluorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4a)

White solid; yield: 35.0%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.37 (s, 1H, CONH), 8.98 (s, 1H, pyrimidine-H), 8.05 (d, J = 8.7 Hz, 2H, Ph-H), 7.86 (s, 1H, pyrimidine-H), 7.79 (dd, J1 = 9.1 Hz, J2 = 5.0 Hz, 2H, Ph-H), 7.45 (d, J = 8.7 Hz, 2H, Ph-H), 7.20 (t, J = 8.9 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.38, 165.13, 159.74, 156.24 (q, J = 35.60 Hz), 154.57, 135.94, 133.17, 130.07, 122.59, 122.52, 122.17, 121.92, 121.82 (q, J = 272.30 Hz), 115.79, 115.57, 107.03; HRMS (ESI) calcd. for C18H12F4N3O2 [M + H]+: 378.3061, found: 378.0851.


#### 2.4.2.N-(4-chlorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4b)

White solid; yield: 42.5%; m.p. 176–179°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.43 (s, 1H, CONH), 8.98 (s, 1H, pyrimidine-H), 8.05 (d, J = 8.5 Hz, 2H, Ph-H), 7.85 (s, 1H, pyrimidine-H), 7.82 (d, J = 8.8 Hz, 2H, Ph-H), 7.45 (d, J = 8.6 Hz, 2H, Ph-H), 7.41 (d, J = 8.8 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.26, 162.10, 159.38, 156.24 (q, J = 35.60 Hz), 143.29, 137.81, 134.89, 134.83, 134.81, 133.75, 132.50, 126.97, 126.96, 126.92, 122.21 (q, J = 273.60 Hz), 106.95; HRMS (ESI) calcd. for C18H12ClF3N3O2 [M + H]+: 394.0565, found: 394.0563.


#### 2.4.3.N-(4-bromophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4c)

White solid; yield: 26.8%; m.p. 168–171°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.42 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.04 (dd, J1 = 8.6, J2 = 6.3 Hz, 2H, Ph-H), 7.84 (s, 1H, pyrimidine-H), 7.76 (d, J = 8.9 Hz, 2H, Ph-H), 7.54 (dd, J1 = 8.8, J2 = 1.3 Hz, 2H, Ph-H), 7.45 (d, J = 8.7 Hz, 1H, Ph-H), 7.41 (d, J = 8.7 Hz, 1H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.37, 165.36, 164.09, 159.73, 156.25 (q, J = 34.6 Hz), 151.28, 139.01, 138.98, 133.07, 132.44, 131.93, 130.15, 122.60, 122.21 (q, J = 273.65 Hz), 121.94, 115.85, 107.00; HRMS (ESI) calcd. for C18H11BrF3N3O2 [M + H]+: 438.0060, found: 438.0057.


#### 2.4.4.N-(4-methoxyphenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4d)

White solid; yield: 62.1%; m.p. 143–145°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.20 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.06 (d, J = 9.0 Hz, 2H, Ph-H), 7.85 (s, 1H, pyrimidine-H), 7.70 (d, J = 8.4 Hz, 2H, Ph-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 6.95 (d, J = 9.0 Hz, 2H, Ph-H), 3.76 (s, 3H, CH3O); 13C NMR (125 MHz, DMSO-d6, ppm) δ 17041, 169.77, 159.76, 156.20 (q, J = 34.95 Hz), 156.06, 154.43, 133.45, 132.65, 129.98, 122.22, 122.09, 121.81 (q, J = 272.85 Hz), 114.23, 107.00, 55.65; HRMS (ESI) calcd. for C19H15F3N3O3 [M + H]+: 390.1060, found: 390.1060.


#### 2.4.5.N-(4-methyphenyl)-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4e)

White solid; yield: 62.1%; m.p. 162–164°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.24 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.18 (d, J = 8.4 Hz, 2H, Ph-H), 7.86 (s, 1H, pyrimidine-H), 7.68 (d, J = 8.4 Hz, 2H, Ph-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 7.18 (d, J = 7.8 Hz, 2H, Ph-H), 2.29 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.41, 165.01, 159.76, 156.20 (q, J = 35.25 Hz), 154.48, 140.34, 137.07, 133.45, 133.14, 130.05, 129.49, 122.10, 121.81(q, J = 272.85 Hz), 120.80, 106.99, 20.97; HRMS (ESI) calcd. for C19H15F3N3O2 [M + H]+: 374.1113, found: 374.1110.


#### 2.4.6.N-(3-chloro-4-fluorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4f)

White solid; yield: 25.6%; m.p. 178-179°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.58 (s, 1H, CONH), 9.06 (s, 1H, pyrimidine-H), 8.18–8.12 (m, 3H, Ph-H), 7.93 (s, 1H, pyrimidine-H), 7.82–7.78 (m, 1H, Ph-H), 7.56–7.48 (m, 3H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.33, 165.34, 159.71, 156.23 (q, J = 35.0 Hz), 155.01, 154.73, 152.60, 136.82, 132.77, 130.12, 121.83 (q, J = 272.85 Hz), 122.23, 121.01, 119.55, 119.37, 117.40, 107.04; HRMS (ESI) calcd. for C18H10F4ClN3O2 [M + Na]+: 434.0293, found: 434.0290.


#### 2.4.7.N-(4-bromo-3-chlorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4g)

White solid; yield: 32.7%; m.p. 187–189°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.57 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.18 (d, J = 2.4 Hz, 1H, Ph-H), 8.08 (d, J = 9.0 Hz, 2H, Ph-H), 7.87 (s, 1H, pyrimidine-H), 7.75 (d, J = 9.0 Hz, 1H, Ph-H), 7.73–7.66 (m, 1H, Ph-H), 7.49 (d, J = 9.0 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.37, 167.43, 165.56, 159.75, 156.41(q, J = 34.8 Hz), 154.86, 140.34, 134.27, 133.40, 132.72, 132.17, 131.99, 130.23, 129.13, 122.62, 122.25(q, J = 272.55 Hz), 120.02, 115.83, 115.36, 110.00, 103.75; HRMS (ESI) calcd. for C18H9F3ClBrN3O2 [M + Na]+: 470.9592, found: 470.9590.


#### 2.4.8. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-phenylbenzamide (4h)

White solid; yield: 30.0%; m.p. 167–169°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.32 (s, 1H, CONH), 8.07 (d, J = 8.4 Hz, 2H, Ph-H), 7.79 (d, J = 7.8 Hz, 2H, Ph-H), 7.60 (s, 1H, pyrimidine-H), 7.45 (d, J = 9.0 Hz, 2H, Ph-H), 7.30 (t, J = 7.8 Hz, 2H, Ph-H), 7.12 (t, J = 7.2 Hz, 2H, Ph-H), 2.52 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.30, 169.70, 165.24, 156.39 (q, J = 35.1 Hz), 155.94, 154.64, 139.62, 130.12, 129.11, 124.20, 122.01, 121.83 (q, J = 272.85 Hz), 120.81, 103.80, 25.93; HRMS (ESI) calcd. for C19H14F3N3O2 [M + H]+: 372.0964, found: 372.0954.


#### 2.4.9. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(2-methyphenyl)benzamide (4i)

White solid; yield: 21.5%; m.p. 168–170°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 9.96 (s, 1H, CONH), 8.11 (d, J = 8.4 Hz, 2H, Ph-H), 7.59 (s, 1H, pyrimidine-H), 7.45 (d, J = 9.0 Hz, 2H, Ph-H), 7.37 (d, J = 7.2 Hz, 2H, Ph-H), 7.29 (d, J = 7.2 Hz, 2H, Ph-H), 7.23 (t, J = 6.0 Hz, 2H, Ph-H), 7.19 (t, J = 7.2 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3), 2.26 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.30, 169.71, 164.96, 156.60, 155.41(q, J = 34.6 Hz), 156.18, 155.94, 154.63, 136.83, 134.22, 132.72, 130.79, 130.07, 127.07, 126.51, 122.21 (q, J = 273.8 Hz), 122.03, 103.76, 25.90, 18.39; HRMS (ESI) calcd. for C20H16F3N3O2 [M + H]+: 386.1121, found: 386.1111.


#### 2.4.10.N-(4-fluorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4j)

White solid, yield: 38.4%, m.p. 175–178°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.38 (s, 1H, CONNH), 8.04 (d, J = 8.7 Hz, 2H, Ph-H), 7.79 (dd, J1 = 9.1, J2 = 5.1 Hz, 2H, Ph-H), 7.58 (s, 1H, pyrimidine-H), 7.43 (d, J = 8.7 Hz, 2H, Ph-H), 7.19 (t, J = 8.9 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3);13C NMR (150 MHz, DMSO-d6, ppm) δ 170.22, 169.66, 165.12, 159.95, 157.54, 156.39 (q, J = 34.8 Hz), 154.62, 135.95, 132.96, 130.06, 122.60, 122.52, 122.24 (q, J = 273.3 Hz), 122.02, 115.77, 115.55, 103.75, 25.88; HRMS (ESI) calcd. for C19H14F4N3O2 [M + H]+: 392.1017, found: 392.1014.


#### 2.4.11.N-(4-chlorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4k)

White solid; yield: 42.5%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.37 (s, 1H, CONH), 8.05 (d, J = 8.8 Hz, 2H, Ph-H), 7.79 (dd, J1 = 3.2, J2 = 6.0 Hz, 2H, Ph-H),7.60 (s, 1H, pyrimidine-H), 7.45 (d, J = 8.7 Hz, 2H, Ph-H), 7.20 (t, J = 8.9 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.24, 169.66, 165.32, 156.40 (q, J = 34.6 Hz), 154.71, 138.56, 132.86, 132.47, 130.13, 129.79, 129.02, 127.76, 122.25 (q, J = 273.6 Hz), 122.05, 103.78, 25.90; HRMS (ESI) calcd. for C19H14ClF3N3O2 [M + H]+: 408.0721, found: 408.0720.


#### 2.4.12.N-(4-bromophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4l)

White solid; yield: 42.5%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.44 (s, 1H, CONH), 8.06 (d, J = 8.8 Hz, 2H, Ph-H), 7.78 (d, J = 8.8 Hz, 2H, Ph-H), 7.60 (s, 1H, pyrimidine-H), 7.56 (d, J = 9.2 Hz, 2H, Ph-H), 7.46 (d, J = 8.8 Hz, 2H, Ph-H), 2.52 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.19, 169.64, 165.33, 156.41 (q, J = 34.6 Hz), 155.01, 154.80, 152.59, 136.83, 132.55, 130.11, 122.21 (q, J = 273.0 Hz), 121.03, 119.55, 119.37, 117.18, 103.79, 25.96; HRMS (ESI) calcd. for C18H11BrF3N3O2 [M + H]+: 450.0068, found: 450.0065.


#### 2.4.13.N-(4-methoxyphenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4m)

White solid; yield: 56.2%; m.p. 154–155°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.21 (s, 1H, –CONH–), 8.04 (d, J = 8.6 Hz, 2H, Ph-H), 7.68 (d, J = 9.0 Hz, 2H, Ph-H), 7.57 (s, 1H, pyrimidine-H), 7.42 (d, J = 8.7 Hz, 2H, Ph-H), 6.92 (d, J = 9.0 Hz, 2H, Ph-H), 3.74 (s, 3H, CH3O), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.26, 169.67, 164.75, 156.39 (q, J = 34.8 Hz), 156.00, 154.46, 133.22, 132.63, 129.95, 122.36, 122.24 (q, J = 273.2 Hz), 121.94, 114.18, 103.74, 55.59, 25.88; HRMS (ESI) calcd. for C20H17F3N3O2 [M + Na]+: 425.1195, found: 425.1196.


#### 2.4.14. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(4-methyphenyl)benzamide (4n)

White solid; yield: 39.9%; m.p. 167–168°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.24 (s, 1H, CONH), 8.04 (d, J = 8.4 Hz, 2H, Ph-H), 7.65 (d, J = 8.0 Hz, 2H, Ph-H), 7.56 (s, 1H, pyrimidine-H), 7.42 (d, J = 8.4 Hz, 2H, Ph-H), 7.15 (d, J = 7.6 Hz, 2H, Ph-H), 2.50 (s, 3H, CH3), 2.26 (s, 3H, CH); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.22, 169.66, 165.01, 156.40 (q, J = 34.8 Hz), 154.49, 136.97, 133.16, 130.00, 129.45, 122.23 (q, J = 273.3 Hz), 121.94, 120.81, 103.68, 25.86, 20.92; HRMS (ESI) calcd. for C19H14ClF3N3O2 [M + H]+: 408.0721, found: 408.0723.


#### 2.4.15. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(4-(trifluoromethoxy)phenyl) benzamide (4o)

White solid; yield: 26.2%; m.p. 164–167°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.51 (s, 1H, CONH), 8.07 (d, J = 8.4 Hz, 2H, Ph-H), 7.92 (d, J = 8.4 Hz, 2H, Ph-H), 7.61 (s, 1H, pyrimidine-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 7.38 (d, J = 8.4 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.25, 169.69, 165.38, 156.65, 156.41 (q, J = 35.25 Hz), 154.77, 144.37, 138.83, 132.82, 130.17, 122.09, 122.05, 121.96, 121.82 (q, J = 272.85 Hz), 121.48 (q, J = 254.25 Hz), 103.76, 25.80; HRMS (ESI) calcd. for C20H13F6N3O3 [M + Na]+: 480.0756, found: 480.0753.


#### 2.4.16.N-(4-bromo-3-chlorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4p)

White solid; yield: 48.0%; m.p. 166–169°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.57 (s, 1H, CONH), 8.18 (d, J = 2.4 Hz, 1H, Ph-H), 8.07 (d, J = 9.0 Hz, 2H, Ph-H), 7.76 (d, J = 9.0 Hz, 1H, Ph-H), 7.73–7.66 (m, 1H, Ph-H), 7.61 (s, 1H, pyrimidine-H), 7.47 (d, J = 9.0 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.23, 169.68, 167.43, 165.54, 156.42 (q, J = 34.9 Hz), 155.01, 154.93, 140.35, 134.25, 133.40, 132.50, 132.17, 131.98, 130.22, 129.13, 122.12, 122.24 (q, J = 273.3 Hz), 122.08, 121.03, 119.55, 117.40, 117.18, 103.79, 25.88. HRMS (ESI) calcd. for C19H12BrClF3N3O2 [M + H]+: 485.9826, found: 485.9825.


#### 2.4.17.N-(3-chloro-4-(trifluoromethoxy)phenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4q)

White solid; yield: 29.0%; m.p. 176–178°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.66 (s, 1H, CONH), 8.20 (d, J = 2.4 Hz, 1H, Ph-H), 8.08 (d, 2H, J = 8.4 Hz, Ph-H), 7.86 (dd, J1 = 2.4 Hz, J2 = 6.6 Hz, 1H, Ph-H), 7.59–7.57 (m, 2H, Ph-H and pyrimidine-H), 7.47 (d, J = 9.0 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.21, 169.69, 165.59, 156.42 (q, J = 34.8 Hz), 154.95, 139.92, 132.42, 130.24, 126.44, 123.99, 122.11, 121.99, 121.81 (q, J = 273.3 Hz), 121.41 (q, J = 256.35 Hz), 120.53, 103.78, 25.88. HRMS (ESI) calcd. for C20H13F6ClN3O3 [M + H]+: 492.0551, found: 492.0544.


### 2.5. In Vitro Antifungal Activity Test

The in vitro antifungal activities againstPhomopsis sp., B. dothidea, and B. cinerea of the target compounds 4a–4q at 50 μg/mL were evaluated by the mycelium growth rate technique [32]. Each compound was dissolved in 1 mL DMSO and 9 mL 0.1% Twain aqueous solution, and then the mixture solution was added to 90 mL potato dextrose agar (PDA) medium to obtain 100 mL mixed PDA medium with the test compound concentration of 50 μg/mL. The mixed PDA mediums were poured into 6 dishes and cooled to room temperature to prepare PDA plates. Then, approximately 0.4 cm diameter mycelia dishes were cut from culture medium and transferred to the middle of PDA plates with a germfree inoculation needle. After that, the inoculated PDA plates were fostered at 27 ± 1°C for 3-4 days. Three replicates were conducted for each treatment. The following formula (1) was used to calculate the inhibition rates I (%), where C (cm) represents the diameter of fungi growth on untreated PDA and T (cm) represents the diameter of fungi on treated PDA:(1)I%=C−TC−0.4×100.


### 2.6. Insecticidal Activity Test

The insecticidal activities againstS. frugiperda and M. separata of the target compounds 4a–4q at 500 μg/mL were performed according to the reported methods [33]. Each compound was added to 0.1 mg/L NP-10 solvent to prepare the test compound solution with 500 µg/mL concentration. Then, approximately 5 cm length maize leaves and 3 cm diameter sweet corn leaves were soaked into the mixed solutions for 10 s and then dried at room temperature and placed in the Petri dish. After that, 30 larvae of second-instar S. frugiperda and M. separata were transferred into the Petri dish and cultivated in the incubator at 27 ± 1°C for 48 h. Three replicates were performed for each treatment. The mortality rates were determined using Abbott’s formula.


## 2.1. Materials and Methods

The melting points were obtained by using an XT-4 binocular microscope (Beijing Tech. Instrument Co., China). NMR spectral recorded on a Bruker Avance NEO 600 NMR spectrometer (Bruker Corporation, MA, USA) using DMSO-d6 as an solvent. HRMS data were obtained on a Thermo Scientific Q Exactive Fucus instrument (Thermo Fisher Scientific, CA, USA). Analytical TLC was performed on silica gel GF254.


## 2.2. General Procedure for the Preparation of Intermediates 1 and 2

Trifluoroacetoacetate (0.1 mol) with ethanol (200 mL) was added to a 500 mL round bottom flask. Then, formamidine hydrochloride (0.1 mol) or acetamidine hydrochloride (0.1 mol) and 1,8-diazabicyclo[5.4.0]undecane-7-ene (DBU, 0.15 mol) were added to the mixture and reacted for 10 h at reflux temperature. After completion, the mixture was cooled to room temperature, acidified with 1 mol/L HCl to pH 7, extracted with ethyl acetate, and evaporated under vacuum to produce intermediate 1. Then, intermediate 1 (0.1 mol), POCl3 (0.2 mol), and CH3CN (240 mL) were added to a 500 mL round bottom flask and reacted for 0.5 h at reflux temperature. After that, diisopropylethylamine (0.12 mol) was added dropwise and continuously reacted for 8 h. After completion, excess POCl3 and CH3CN were removed by distillation, and then ice-water mixture (120 mL) was added. Finally, the mixture was alkalified with 5 mol/L NaOH to pH 9 and extracted using CH2Cl2 to give intermediate 2.


## 2.3. General Procedure for the Preparation of the Key Intermediate 3

To a 100 mL round bottom flask, intermediate 2 (0.012 mol) dissolved in acetone (10 mL), Cs2CO3 (0.02 mol), and 4-hydroxybenzoic acid (0.01 mol) were added and reacted for 2-3 h at room temperature. After the completion of reaction, the excess solvent was removed, and the residue was added to distilled water (50 mL) and acidified with concentrated HCl to pH 2-3. The precipitate was filtered and recrystallized from ethanol to give key intermediate 3. The structures of intermediate 3 were confirmed by 1H NMR and 13C NMR. The physical characteristics and 1H NMR and 13C NMR data for intermediate 3 are shown as follows.


### 2.3.1. 4-((6-(Trifluoromethyl)pyrimidine-4-yl)oxy)benzoic acid (3a)

White solid; yield: 80.1%; m.p. 147-148°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 9.02 (s, 1H, pyrimidine-H), 8.41 (s, 1H, pyrimidine-H), 8.21 (d, 1H, J = 8.4 Hz, Ph-H), 7.86 (d, J = 8.4 Hz, 1H, Ph-H), 7.70 (t, J = 7.2 Hz, 1H, Ph-H), 7.70 (t, J = 7.8 Hz, 1H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.34, 159.75, 156.12(q, J = 36.0 Hz), 143.24, 129.97, 128.63, 126.01, 121.53 (q, J = 272.85 Hz), 120.46, 109.99, 105.44.


### 2.3.2. 4-((2-Methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzoic acid (3b)

White solid; yield: 70.0%; m.p. 145-146°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 12.56 (s, 1H, COOH), 7.80 (d, J = 8.4 Hz, 2H, Ph-H), 7.48 (s, 1H, pyrimidine-H), 6.83 (d, J = 8.4 Hz, 2H, Ph-H), 2.35 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 167.63, 162.69, 162.06, 151.96 (q, J = 35.25 Hz), 131.98, 122.09 (q, J = 273.00 Hz), 121.82, 115.56, 111.07, 25.90.


## 2.3.1. 4-((6-(Trifluoromethyl)pyrimidine-4-yl)oxy)benzoic acid (3a)

White solid; yield: 80.1%; m.p. 147-148°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 9.02 (s, 1H, pyrimidine-H), 8.41 (s, 1H, pyrimidine-H), 8.21 (d, 1H, J = 8.4 Hz, Ph-H), 7.86 (d, J = 8.4 Hz, 1H, Ph-H), 7.70 (t, J = 7.2 Hz, 1H, Ph-H), 7.70 (t, J = 7.8 Hz, 1H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.34, 159.75, 156.12(q, J = 36.0 Hz), 143.24, 129.97, 128.63, 126.01, 121.53 (q, J = 272.85 Hz), 120.46, 109.99, 105.44.


## 2.3.2. 4-((2-Methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzoic acid (3b)

White solid; yield: 70.0%; m.p. 145-146°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 12.56 (s, 1H, COOH), 7.80 (d, J = 8.4 Hz, 2H, Ph-H), 7.48 (s, 1H, pyrimidine-H), 6.83 (d, J = 8.4 Hz, 2H, Ph-H), 2.35 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 167.63, 162.69, 162.06, 151.96 (q, J = 35.25 Hz), 131.98, 122.09 (q, J = 273.00 Hz), 121.82, 115.56, 111.07, 25.90.


## 2.4. General Procedure for the Preparation of the Target Compounds (4a–4q)

To a 50 mL round bottom flask, the key intermediate 3 (0.024 mol), dichloromethane (20 mL), aromatic amides (0.02 mol), dimethylaminopyridine (DMAP, 0.0004 mol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 0.03 mol) were added, respectively. The reaction was carried out at room temperature for 8–10 h. After the completion of the reaction, the solvent was evaporated under vacuum condition and then the residue was recrystallized from ethanol to give pure target compounds4a–4q. The physical characteristics, 1H NMR, 13C NMR, and HRMS data for all the target compounds are shown in Supplementary Materials.


### 2.4.1.N-(4-fluorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4a)

White solid; yield: 35.0%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.37 (s, 1H, CONH), 8.98 (s, 1H, pyrimidine-H), 8.05 (d, J = 8.7 Hz, 2H, Ph-H), 7.86 (s, 1H, pyrimidine-H), 7.79 (dd, J1 = 9.1 Hz, J2 = 5.0 Hz, 2H, Ph-H), 7.45 (d, J = 8.7 Hz, 2H, Ph-H), 7.20 (t, J = 8.9 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.38, 165.13, 159.74, 156.24 (q, J = 35.60 Hz), 154.57, 135.94, 133.17, 130.07, 122.59, 122.52, 122.17, 121.92, 121.82 (q, J = 272.30 Hz), 115.79, 115.57, 107.03; HRMS (ESI) calcd. for C18H12F4N3O2 [M + H]+: 378.3061, found: 378.0851.


### 2.4.2.N-(4-chlorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4b)

White solid; yield: 42.5%; m.p. 176–179°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.43 (s, 1H, CONH), 8.98 (s, 1H, pyrimidine-H), 8.05 (d, J = 8.5 Hz, 2H, Ph-H), 7.85 (s, 1H, pyrimidine-H), 7.82 (d, J = 8.8 Hz, 2H, Ph-H), 7.45 (d, J = 8.6 Hz, 2H, Ph-H), 7.41 (d, J = 8.8 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.26, 162.10, 159.38, 156.24 (q, J = 35.60 Hz), 143.29, 137.81, 134.89, 134.83, 134.81, 133.75, 132.50, 126.97, 126.96, 126.92, 122.21 (q, J = 273.60 Hz), 106.95; HRMS (ESI) calcd. for C18H12ClF3N3O2 [M + H]+: 394.0565, found: 394.0563.


### 2.4.3.N-(4-bromophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4c)

White solid; yield: 26.8%; m.p. 168–171°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.42 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.04 (dd, J1 = 8.6, J2 = 6.3 Hz, 2H, Ph-H), 7.84 (s, 1H, pyrimidine-H), 7.76 (d, J = 8.9 Hz, 2H, Ph-H), 7.54 (dd, J1 = 8.8, J2 = 1.3 Hz, 2H, Ph-H), 7.45 (d, J = 8.7 Hz, 1H, Ph-H), 7.41 (d, J = 8.7 Hz, 1H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.37, 165.36, 164.09, 159.73, 156.25 (q, J = 34.6 Hz), 151.28, 139.01, 138.98, 133.07, 132.44, 131.93, 130.15, 122.60, 122.21 (q, J = 273.65 Hz), 121.94, 115.85, 107.00; HRMS (ESI) calcd. for C18H11BrF3N3O2 [M + H]+: 438.0060, found: 438.0057.


### 2.4.4.N-(4-methoxyphenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4d)

White solid; yield: 62.1%; m.p. 143–145°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.20 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.06 (d, J = 9.0 Hz, 2H, Ph-H), 7.85 (s, 1H, pyrimidine-H), 7.70 (d, J = 8.4 Hz, 2H, Ph-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 6.95 (d, J = 9.0 Hz, 2H, Ph-H), 3.76 (s, 3H, CH3O); 13C NMR (125 MHz, DMSO-d6, ppm) δ 17041, 169.77, 159.76, 156.20 (q, J = 34.95 Hz), 156.06, 154.43, 133.45, 132.65, 129.98, 122.22, 122.09, 121.81 (q, J = 272.85 Hz), 114.23, 107.00, 55.65; HRMS (ESI) calcd. for C19H15F3N3O3 [M + H]+: 390.1060, found: 390.1060.


### 2.4.5.N-(4-methyphenyl)-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4e)

White solid; yield: 62.1%; m.p. 162–164°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.24 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.18 (d, J = 8.4 Hz, 2H, Ph-H), 7.86 (s, 1H, pyrimidine-H), 7.68 (d, J = 8.4 Hz, 2H, Ph-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 7.18 (d, J = 7.8 Hz, 2H, Ph-H), 2.29 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.41, 165.01, 159.76, 156.20 (q, J = 35.25 Hz), 154.48, 140.34, 137.07, 133.45, 133.14, 130.05, 129.49, 122.10, 121.81(q, J = 272.85 Hz), 120.80, 106.99, 20.97; HRMS (ESI) calcd. for C19H15F3N3O2 [M + H]+: 374.1113, found: 374.1110.


### 2.4.6.N-(3-chloro-4-fluorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4f)

White solid; yield: 25.6%; m.p. 178-179°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.58 (s, 1H, CONH), 9.06 (s, 1H, pyrimidine-H), 8.18–8.12 (m, 3H, Ph-H), 7.93 (s, 1H, pyrimidine-H), 7.82–7.78 (m, 1H, Ph-H), 7.56–7.48 (m, 3H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.33, 165.34, 159.71, 156.23 (q, J = 35.0 Hz), 155.01, 154.73, 152.60, 136.82, 132.77, 130.12, 121.83 (q, J = 272.85 Hz), 122.23, 121.01, 119.55, 119.37, 117.40, 107.04; HRMS (ESI) calcd. for C18H10F4ClN3O2 [M + Na]+: 434.0293, found: 434.0290.


### 2.4.7.N-(4-bromo-3-chlorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4g)

White solid; yield: 32.7%; m.p. 187–189°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.57 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.18 (d, J = 2.4 Hz, 1H, Ph-H), 8.08 (d, J = 9.0 Hz, 2H, Ph-H), 7.87 (s, 1H, pyrimidine-H), 7.75 (d, J = 9.0 Hz, 1H, Ph-H), 7.73–7.66 (m, 1H, Ph-H), 7.49 (d, J = 9.0 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.37, 167.43, 165.56, 159.75, 156.41(q, J = 34.8 Hz), 154.86, 140.34, 134.27, 133.40, 132.72, 132.17, 131.99, 130.23, 129.13, 122.62, 122.25(q, J = 272.55 Hz), 120.02, 115.83, 115.36, 110.00, 103.75; HRMS (ESI) calcd. for C18H9F3ClBrN3O2 [M + Na]+: 470.9592, found: 470.9590.


### 2.4.8. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-phenylbenzamide (4h)

White solid; yield: 30.0%; m.p. 167–169°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.32 (s, 1H, CONH), 8.07 (d, J = 8.4 Hz, 2H, Ph-H), 7.79 (d, J = 7.8 Hz, 2H, Ph-H), 7.60 (s, 1H, pyrimidine-H), 7.45 (d, J = 9.0 Hz, 2H, Ph-H), 7.30 (t, J = 7.8 Hz, 2H, Ph-H), 7.12 (t, J = 7.2 Hz, 2H, Ph-H), 2.52 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.30, 169.70, 165.24, 156.39 (q, J = 35.1 Hz), 155.94, 154.64, 139.62, 130.12, 129.11, 124.20, 122.01, 121.83 (q, J = 272.85 Hz), 120.81, 103.80, 25.93; HRMS (ESI) calcd. for C19H14F3N3O2 [M + H]+: 372.0964, found: 372.0954.


### 2.4.9. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(2-methyphenyl)benzamide (4i)

White solid; yield: 21.5%; m.p. 168–170°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 9.96 (s, 1H, CONH), 8.11 (d, J = 8.4 Hz, 2H, Ph-H), 7.59 (s, 1H, pyrimidine-H), 7.45 (d, J = 9.0 Hz, 2H, Ph-H), 7.37 (d, J = 7.2 Hz, 2H, Ph-H), 7.29 (d, J = 7.2 Hz, 2H, Ph-H), 7.23 (t, J = 6.0 Hz, 2H, Ph-H), 7.19 (t, J = 7.2 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3), 2.26 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.30, 169.71, 164.96, 156.60, 155.41(q, J = 34.6 Hz), 156.18, 155.94, 154.63, 136.83, 134.22, 132.72, 130.79, 130.07, 127.07, 126.51, 122.21 (q, J = 273.8 Hz), 122.03, 103.76, 25.90, 18.39; HRMS (ESI) calcd. for C20H16F3N3O2 [M + H]+: 386.1121, found: 386.1111.


### 2.4.10.N-(4-fluorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4j)

White solid, yield: 38.4%, m.p. 175–178°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.38 (s, 1H, CONNH), 8.04 (d, J = 8.7 Hz, 2H, Ph-H), 7.79 (dd, J1 = 9.1, J2 = 5.1 Hz, 2H, Ph-H), 7.58 (s, 1H, pyrimidine-H), 7.43 (d, J = 8.7 Hz, 2H, Ph-H), 7.19 (t, J = 8.9 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3);13C NMR (150 MHz, DMSO-d6, ppm) δ 170.22, 169.66, 165.12, 159.95, 157.54, 156.39 (q, J = 34.8 Hz), 154.62, 135.95, 132.96, 130.06, 122.60, 122.52, 122.24 (q, J = 273.3 Hz), 122.02, 115.77, 115.55, 103.75, 25.88; HRMS (ESI) calcd. for C19H14F4N3O2 [M + H]+: 392.1017, found: 392.1014.


### 2.4.11.N-(4-chlorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4k)

White solid; yield: 42.5%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.37 (s, 1H, CONH), 8.05 (d, J = 8.8 Hz, 2H, Ph-H), 7.79 (dd, J1 = 3.2, J2 = 6.0 Hz, 2H, Ph-H),7.60 (s, 1H, pyrimidine-H), 7.45 (d, J = 8.7 Hz, 2H, Ph-H), 7.20 (t, J = 8.9 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.24, 169.66, 165.32, 156.40 (q, J = 34.6 Hz), 154.71, 138.56, 132.86, 132.47, 130.13, 129.79, 129.02, 127.76, 122.25 (q, J = 273.6 Hz), 122.05, 103.78, 25.90; HRMS (ESI) calcd. for C19H14ClF3N3O2 [M + H]+: 408.0721, found: 408.0720.


### 2.4.12.N-(4-bromophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4l)

White solid; yield: 42.5%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.44 (s, 1H, CONH), 8.06 (d, J = 8.8 Hz, 2H, Ph-H), 7.78 (d, J = 8.8 Hz, 2H, Ph-H), 7.60 (s, 1H, pyrimidine-H), 7.56 (d, J = 9.2 Hz, 2H, Ph-H), 7.46 (d, J = 8.8 Hz, 2H, Ph-H), 2.52 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.19, 169.64, 165.33, 156.41 (q, J = 34.6 Hz), 155.01, 154.80, 152.59, 136.83, 132.55, 130.11, 122.21 (q, J = 273.0 Hz), 121.03, 119.55, 119.37, 117.18, 103.79, 25.96; HRMS (ESI) calcd. for C18H11BrF3N3O2 [M + H]+: 450.0068, found: 450.0065.


### 2.4.13.N-(4-methoxyphenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4m)

White solid; yield: 56.2%; m.p. 154–155°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.21 (s, 1H, –CONH–), 8.04 (d, J = 8.6 Hz, 2H, Ph-H), 7.68 (d, J = 9.0 Hz, 2H, Ph-H), 7.57 (s, 1H, pyrimidine-H), 7.42 (d, J = 8.7 Hz, 2H, Ph-H), 6.92 (d, J = 9.0 Hz, 2H, Ph-H), 3.74 (s, 3H, CH3O), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.26, 169.67, 164.75, 156.39 (q, J = 34.8 Hz), 156.00, 154.46, 133.22, 132.63, 129.95, 122.36, 122.24 (q, J = 273.2 Hz), 121.94, 114.18, 103.74, 55.59, 25.88; HRMS (ESI) calcd. for C20H17F3N3O2 [M + Na]+: 425.1195, found: 425.1196.


### 2.4.14. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(4-methyphenyl)benzamide (4n)

White solid; yield: 39.9%; m.p. 167–168°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.24 (s, 1H, CONH), 8.04 (d, J = 8.4 Hz, 2H, Ph-H), 7.65 (d, J = 8.0 Hz, 2H, Ph-H), 7.56 (s, 1H, pyrimidine-H), 7.42 (d, J = 8.4 Hz, 2H, Ph-H), 7.15 (d, J = 7.6 Hz, 2H, Ph-H), 2.50 (s, 3H, CH3), 2.26 (s, 3H, CH); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.22, 169.66, 165.01, 156.40 (q, J = 34.8 Hz), 154.49, 136.97, 133.16, 130.00, 129.45, 122.23 (q, J = 273.3 Hz), 121.94, 120.81, 103.68, 25.86, 20.92; HRMS (ESI) calcd. for C19H14ClF3N3O2 [M + H]+: 408.0721, found: 408.0723.


### 2.4.15. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(4-(trifluoromethoxy)phenyl) benzamide (4o)

White solid; yield: 26.2%; m.p. 164–167°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.51 (s, 1H, CONH), 8.07 (d, J = 8.4 Hz, 2H, Ph-H), 7.92 (d, J = 8.4 Hz, 2H, Ph-H), 7.61 (s, 1H, pyrimidine-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 7.38 (d, J = 8.4 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.25, 169.69, 165.38, 156.65, 156.41 (q, J = 35.25 Hz), 154.77, 144.37, 138.83, 132.82, 130.17, 122.09, 122.05, 121.96, 121.82 (q, J = 272.85 Hz), 121.48 (q, J = 254.25 Hz), 103.76, 25.80; HRMS (ESI) calcd. for C20H13F6N3O3 [M + Na]+: 480.0756, found: 480.0753.


### 2.4.16.N-(4-bromo-3-chlorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4p)

White solid; yield: 48.0%; m.p. 166–169°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.57 (s, 1H, CONH), 8.18 (d, J = 2.4 Hz, 1H, Ph-H), 8.07 (d, J = 9.0 Hz, 2H, Ph-H), 7.76 (d, J = 9.0 Hz, 1H, Ph-H), 7.73–7.66 (m, 1H, Ph-H), 7.61 (s, 1H, pyrimidine-H), 7.47 (d, J = 9.0 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.23, 169.68, 167.43, 165.54, 156.42 (q, J = 34.9 Hz), 155.01, 154.93, 140.35, 134.25, 133.40, 132.50, 132.17, 131.98, 130.22, 129.13, 122.12, 122.24 (q, J = 273.3 Hz), 122.08, 121.03, 119.55, 117.40, 117.18, 103.79, 25.88. HRMS (ESI) calcd. for C19H12BrClF3N3O2 [M + H]+: 485.9826, found: 485.9825.


### 2.4.17.N-(3-chloro-4-(trifluoromethoxy)phenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4q)

White solid; yield: 29.0%; m.p. 176–178°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.66 (s, 1H, CONH), 8.20 (d, J = 2.4 Hz, 1H, Ph-H), 8.08 (d, 2H, J = 8.4 Hz, Ph-H), 7.86 (dd, J1 = 2.4 Hz, J2 = 6.6 Hz, 1H, Ph-H), 7.59–7.57 (m, 2H, Ph-H and pyrimidine-H), 7.47 (d, J = 9.0 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.21, 169.69, 165.59, 156.42 (q, J = 34.8 Hz), 154.95, 139.92, 132.42, 130.24, 126.44, 123.99, 122.11, 121.99, 121.81 (q, J = 273.3 Hz), 121.41 (q, J = 256.35 Hz), 120.53, 103.78, 25.88. HRMS (ESI) calcd. for C20H13F6ClN3O3 [M + H]+: 492.0551, found: 492.0544.


## 2.4.1.N-(4-fluorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4a)

White solid; yield: 35.0%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.37 (s, 1H, CONH), 8.98 (s, 1H, pyrimidine-H), 8.05 (d, J = 8.7 Hz, 2H, Ph-H), 7.86 (s, 1H, pyrimidine-H), 7.79 (dd, J1 = 9.1 Hz, J2 = 5.0 Hz, 2H, Ph-H), 7.45 (d, J = 8.7 Hz, 2H, Ph-H), 7.20 (t, J = 8.9 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.38, 165.13, 159.74, 156.24 (q, J = 35.60 Hz), 154.57, 135.94, 133.17, 130.07, 122.59, 122.52, 122.17, 121.92, 121.82 (q, J = 272.30 Hz), 115.79, 115.57, 107.03; HRMS (ESI) calcd. for C18H12F4N3O2 [M + H]+: 378.3061, found: 378.0851.


## 2.4.2.N-(4-chlorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4b)

White solid; yield: 42.5%; m.p. 176–179°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.43 (s, 1H, CONH), 8.98 (s, 1H, pyrimidine-H), 8.05 (d, J = 8.5 Hz, 2H, Ph-H), 7.85 (s, 1H, pyrimidine-H), 7.82 (d, J = 8.8 Hz, 2H, Ph-H), 7.45 (d, J = 8.6 Hz, 2H, Ph-H), 7.41 (d, J = 8.8 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.26, 162.10, 159.38, 156.24 (q, J = 35.60 Hz), 143.29, 137.81, 134.89, 134.83, 134.81, 133.75, 132.50, 126.97, 126.96, 126.92, 122.21 (q, J = 273.60 Hz), 106.95; HRMS (ESI) calcd. for C18H12ClF3N3O2 [M + H]+: 394.0565, found: 394.0563.


## 2.4.3.N-(4-bromophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4c)

White solid; yield: 26.8%; m.p. 168–171°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.42 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.04 (dd, J1 = 8.6, J2 = 6.3 Hz, 2H, Ph-H), 7.84 (s, 1H, pyrimidine-H), 7.76 (d, J = 8.9 Hz, 2H, Ph-H), 7.54 (dd, J1 = 8.8, J2 = 1.3 Hz, 2H, Ph-H), 7.45 (d, J = 8.7 Hz, 1H, Ph-H), 7.41 (d, J = 8.7 Hz, 1H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.37, 165.36, 164.09, 159.73, 156.25 (q, J = 34.6 Hz), 151.28, 139.01, 138.98, 133.07, 132.44, 131.93, 130.15, 122.60, 122.21 (q, J = 273.65 Hz), 121.94, 115.85, 107.00; HRMS (ESI) calcd. for C18H11BrF3N3O2 [M + H]+: 438.0060, found: 438.0057.


## 2.4.4.N-(4-methoxyphenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4d)

White solid; yield: 62.1%; m.p. 143–145°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.20 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.06 (d, J = 9.0 Hz, 2H, Ph-H), 7.85 (s, 1H, pyrimidine-H), 7.70 (d, J = 8.4 Hz, 2H, Ph-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 6.95 (d, J = 9.0 Hz, 2H, Ph-H), 3.76 (s, 3H, CH3O); 13C NMR (125 MHz, DMSO-d6, ppm) δ 17041, 169.77, 159.76, 156.20 (q, J = 34.95 Hz), 156.06, 154.43, 133.45, 132.65, 129.98, 122.22, 122.09, 121.81 (q, J = 272.85 Hz), 114.23, 107.00, 55.65; HRMS (ESI) calcd. for C19H15F3N3O3 [M + H]+: 390.1060, found: 390.1060.


## 2.4.5.N-(4-methyphenyl)-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4e)

White solid; yield: 62.1%; m.p. 162–164°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.24 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.18 (d, J = 8.4 Hz, 2H, Ph-H), 7.86 (s, 1H, pyrimidine-H), 7.68 (d, J = 8.4 Hz, 2H, Ph-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 7.18 (d, J = 7.8 Hz, 2H, Ph-H), 2.29 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.41, 165.01, 159.76, 156.20 (q, J = 35.25 Hz), 154.48, 140.34, 137.07, 133.45, 133.14, 130.05, 129.49, 122.10, 121.81(q, J = 272.85 Hz), 120.80, 106.99, 20.97; HRMS (ESI) calcd. for C19H15F3N3O2 [M + H]+: 374.1113, found: 374.1110.


## 2.4.6.N-(3-chloro-4-fluorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4f)

White solid; yield: 25.6%; m.p. 178-179°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.58 (s, 1H, CONH), 9.06 (s, 1H, pyrimidine-H), 8.18–8.12 (m, 3H, Ph-H), 7.93 (s, 1H, pyrimidine-H), 7.82–7.78 (m, 1H, Ph-H), 7.56–7.48 (m, 3H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.33, 165.34, 159.71, 156.23 (q, J = 35.0 Hz), 155.01, 154.73, 152.60, 136.82, 132.77, 130.12, 121.83 (q, J = 272.85 Hz), 122.23, 121.01, 119.55, 119.37, 117.40, 107.04; HRMS (ESI) calcd. for C18H10F4ClN3O2 [M + Na]+: 434.0293, found: 434.0290.


## 2.4.7.N-(4-bromo-3-chlorophenyl)-4-((6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4g)

White solid; yield: 32.7%; m.p. 187–189°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.57 (s, 1H, CONH), 8.99 (s, 1H, pyrimidine-H), 8.18 (d, J = 2.4 Hz, 1H, Ph-H), 8.08 (d, J = 9.0 Hz, 2H, Ph-H), 7.87 (s, 1H, pyrimidine-H), 7.75 (d, J = 9.0 Hz, 1H, Ph-H), 7.73–7.66 (m, 1H, Ph-H), 7.49 (d, J = 9.0 Hz, 2H, Ph-H); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.37, 167.43, 165.56, 159.75, 156.41(q, J = 34.8 Hz), 154.86, 140.34, 134.27, 133.40, 132.72, 132.17, 131.99, 130.23, 129.13, 122.62, 122.25(q, J = 272.55 Hz), 120.02, 115.83, 115.36, 110.00, 103.75; HRMS (ESI) calcd. for C18H9F3ClBrN3O2 [M + Na]+: 470.9592, found: 470.9590.


## 2.4.8. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-phenylbenzamide (4h)

White solid; yield: 30.0%; m.p. 167–169°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.32 (s, 1H, CONH), 8.07 (d, J = 8.4 Hz, 2H, Ph-H), 7.79 (d, J = 7.8 Hz, 2H, Ph-H), 7.60 (s, 1H, pyrimidine-H), 7.45 (d, J = 9.0 Hz, 2H, Ph-H), 7.30 (t, J = 7.8 Hz, 2H, Ph-H), 7.12 (t, J = 7.2 Hz, 2H, Ph-H), 2.52 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.30, 169.70, 165.24, 156.39 (q, J = 35.1 Hz), 155.94, 154.64, 139.62, 130.12, 129.11, 124.20, 122.01, 121.83 (q, J = 272.85 Hz), 120.81, 103.80, 25.93; HRMS (ESI) calcd. for C19H14F3N3O2 [M + H]+: 372.0964, found: 372.0954.


## 2.4.9. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(2-methyphenyl)benzamide (4i)

White solid; yield: 21.5%; m.p. 168–170°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 9.96 (s, 1H, CONH), 8.11 (d, J = 8.4 Hz, 2H, Ph-H), 7.59 (s, 1H, pyrimidine-H), 7.45 (d, J = 9.0 Hz, 2H, Ph-H), 7.37 (d, J = 7.2 Hz, 2H, Ph-H), 7.29 (d, J = 7.2 Hz, 2H, Ph-H), 7.23 (t, J = 6.0 Hz, 2H, Ph-H), 7.19 (t, J = 7.2 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3), 2.26 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.30, 169.71, 164.96, 156.60, 155.41(q, J = 34.6 Hz), 156.18, 155.94, 154.63, 136.83, 134.22, 132.72, 130.79, 130.07, 127.07, 126.51, 122.21 (q, J = 273.8 Hz), 122.03, 103.76, 25.90, 18.39; HRMS (ESI) calcd. for C20H16F3N3O2 [M + H]+: 386.1121, found: 386.1111.


## 2.4.10.N-(4-fluorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4j)

White solid, yield: 38.4%, m.p. 175–178°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.38 (s, 1H, CONNH), 8.04 (d, J = 8.7 Hz, 2H, Ph-H), 7.79 (dd, J1 = 9.1, J2 = 5.1 Hz, 2H, Ph-H), 7.58 (s, 1H, pyrimidine-H), 7.43 (d, J = 8.7 Hz, 2H, Ph-H), 7.19 (t, J = 8.9 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3);13C NMR (150 MHz, DMSO-d6, ppm) δ 170.22, 169.66, 165.12, 159.95, 157.54, 156.39 (q, J = 34.8 Hz), 154.62, 135.95, 132.96, 130.06, 122.60, 122.52, 122.24 (q, J = 273.3 Hz), 122.02, 115.77, 115.55, 103.75, 25.88; HRMS (ESI) calcd. for C19H14F4N3O2 [M + H]+: 392.1017, found: 392.1014.


## 2.4.11.N-(4-chlorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4k)

White solid; yield: 42.5%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.37 (s, 1H, CONH), 8.05 (d, J = 8.8 Hz, 2H, Ph-H), 7.79 (dd, J1 = 3.2, J2 = 6.0 Hz, 2H, Ph-H),7.60 (s, 1H, pyrimidine-H), 7.45 (d, J = 8.7 Hz, 2H, Ph-H), 7.20 (t, J = 8.9 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.24, 169.66, 165.32, 156.40 (q, J = 34.6 Hz), 154.71, 138.56, 132.86, 132.47, 130.13, 129.79, 129.02, 127.76, 122.25 (q, J = 273.6 Hz), 122.05, 103.78, 25.90; HRMS (ESI) calcd. for C19H14ClF3N3O2 [M + H]+: 408.0721, found: 408.0720.


## 2.4.12.N-(4-bromophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzamide (4l)

White solid; yield: 42.5%; m.p. 172–174°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.44 (s, 1H, CONH), 8.06 (d, J = 8.8 Hz, 2H, Ph-H), 7.78 (d, J = 8.8 Hz, 2H, Ph-H), 7.60 (s, 1H, pyrimidine-H), 7.56 (d, J = 9.2 Hz, 2H, Ph-H), 7.46 (d, J = 8.8 Hz, 2H, Ph-H), 2.52 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.19, 169.64, 165.33, 156.41 (q, J = 34.6 Hz), 155.01, 154.80, 152.59, 136.83, 132.55, 130.11, 122.21 (q, J = 273.0 Hz), 121.03, 119.55, 119.37, 117.18, 103.79, 25.96; HRMS (ESI) calcd. for C18H11BrF3N3O2 [M + H]+: 450.0068, found: 450.0065.


## 2.4.13.N-(4-methoxyphenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4m)

White solid; yield: 56.2%; m.p. 154–155°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.21 (s, 1H, –CONH–), 8.04 (d, J = 8.6 Hz, 2H, Ph-H), 7.68 (d, J = 9.0 Hz, 2H, Ph-H), 7.57 (s, 1H, pyrimidine-H), 7.42 (d, J = 8.7 Hz, 2H, Ph-H), 6.92 (d, J = 9.0 Hz, 2H, Ph-H), 3.74 (s, 3H, CH3O), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.26, 169.67, 164.75, 156.39 (q, J = 34.8 Hz), 156.00, 154.46, 133.22, 132.63, 129.95, 122.36, 122.24 (q, J = 273.2 Hz), 121.94, 114.18, 103.74, 55.59, 25.88; HRMS (ESI) calcd. for C20H17F3N3O2 [M + Na]+: 425.1195, found: 425.1196.


## 2.4.14. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(4-methyphenyl)benzamide (4n)

White solid; yield: 39.9%; m.p. 167–168°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.24 (s, 1H, CONH), 8.04 (d, J = 8.4 Hz, 2H, Ph-H), 7.65 (d, J = 8.0 Hz, 2H, Ph-H), 7.56 (s, 1H, pyrimidine-H), 7.42 (d, J = 8.4 Hz, 2H, Ph-H), 7.15 (d, J = 7.6 Hz, 2H, Ph-H), 2.50 (s, 3H, CH3), 2.26 (s, 3H, CH); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.22, 169.66, 165.01, 156.40 (q, J = 34.8 Hz), 154.49, 136.97, 133.16, 130.00, 129.45, 122.23 (q, J = 273.3 Hz), 121.94, 120.81, 103.68, 25.86, 20.92; HRMS (ESI) calcd. for C19H14ClF3N3O2 [M + H]+: 408.0721, found: 408.0723.


## 2.4.15. 4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)-N-(4-(trifluoromethoxy)phenyl) benzamide (4o)

White solid; yield: 26.2%; m.p. 164–167°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.51 (s, 1H, CONH), 8.07 (d, J = 8.4 Hz, 2H, Ph-H), 7.92 (d, J = 8.4 Hz, 2H, Ph-H), 7.61 (s, 1H, pyrimidine-H), 7.46 (d, J = 8.4 Hz, 2H, Ph-H), 7.38 (d, J = 8.4 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.25, 169.69, 165.38, 156.65, 156.41 (q, J = 35.25 Hz), 154.77, 144.37, 138.83, 132.82, 130.17, 122.09, 122.05, 121.96, 121.82 (q, J = 272.85 Hz), 121.48 (q, J = 254.25 Hz), 103.76, 25.80; HRMS (ESI) calcd. for C20H13F6N3O3 [M + Na]+: 480.0756, found: 480.0753.


## 2.4.16.N-(4-bromo-3-chlorophenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4p)

White solid; yield: 48.0%; m.p. 166–169°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.57 (s, 1H, CONH), 8.18 (d, J = 2.4 Hz, 1H, Ph-H), 8.07 (d, J = 9.0 Hz, 2H, Ph-H), 7.76 (d, J = 9.0 Hz, 1H, Ph-H), 7.73–7.66 (m, 1H, Ph-H), 7.61 (s, 1H, pyrimidine-H), 7.47 (d, J = 9.0 Hz, 2H, Ph-H), 2.51 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.23, 169.68, 167.43, 165.54, 156.42 (q, J = 34.9 Hz), 155.01, 154.93, 140.35, 134.25, 133.40, 132.50, 132.17, 131.98, 130.22, 129.13, 122.12, 122.24 (q, J = 273.3 Hz), 122.08, 121.03, 119.55, 117.40, 117.18, 103.79, 25.88. HRMS (ESI) calcd. for C19H12BrClF3N3O2 [M + H]+: 485.9826, found: 485.9825.


## 2.4.17.N-(3-chloro-4-(trifluoromethoxy)phenyl)-4-((2-methyl-6-(trifluoromethyl)pyrimidine-4-yl)oxy)benzamide (4q)

White solid; yield: 29.0%; m.p. 176–178°C;1H NMR (600 MHz, DMSO-d6, ppm) δ 10.66 (s, 1H, CONH), 8.20 (d, J = 2.4 Hz, 1H, Ph-H), 8.08 (d, 2H, J = 8.4 Hz, Ph-H), 7.86 (dd, J1 = 2.4 Hz, J2 = 6.6 Hz, 1H, Ph-H), 7.59–7.57 (m, 2H, Ph-H and pyrimidine-H), 7.47 (d, J = 9.0 Hz, 2H, Ph-H), 2.53 (s, 3H, CH3); 13C NMR (150 MHz, DMSO-d6, ppm) δ 170.21, 169.69, 165.59, 156.42 (q, J = 34.8 Hz), 154.95, 139.92, 132.42, 130.24, 126.44, 123.99, 122.11, 121.99, 121.81 (q, J = 273.3 Hz), 121.41 (q, J = 256.35 Hz), 120.53, 103.78, 25.88. HRMS (ESI) calcd. for C20H13F6ClN3O3 [M + H]+: 492.0551, found: 492.0544.


## 2.5. In Vitro Antifungal Activity Test

The in vitro antifungal activities againstPhomopsis sp., B. dothidea, and B. cinerea of the target compounds 4a–4q at 50 μg/mL were evaluated by the mycelium growth rate technique [32]. Each compound was dissolved in 1 mL DMSO and 9 mL 0.1% Twain aqueous solution, and then the mixture solution was added to 90 mL potato dextrose agar (PDA) medium to obtain 100 mL mixed PDA medium with the test compound concentration of 50 μg/mL. The mixed PDA mediums were poured into 6 dishes and cooled to room temperature to prepare PDA plates. Then, approximately 0.4 cm diameter mycelia dishes were cut from culture medium and transferred to the middle of PDA plates with a germfree inoculation needle. After that, the inoculated PDA plates were fostered at 27 ± 1°C for 3-4 days. Three replicates were conducted for each treatment. The following formula (1) was used to calculate the inhibition rates I (%), where C (cm) represents the diameter of fungi growth on untreated PDA and T (cm) represents the diameter of fungi on treated PDA:(1)I%=C−TC−0.4×100.


## 2.6. Insecticidal Activity Test

The insecticidal activities againstS. frugiperda and M. separata of the target compounds 4a–4q at 500 μg/mL were performed according to the reported methods [33]. Each compound was added to 0.1 mg/L NP-10 solvent to prepare the test compound solution with 500 µg/mL concentration. Then, approximately 5 cm length maize leaves and 3 cm diameter sweet corn leaves were soaked into the mixed solutions for 10 s and then dried at room temperature and placed in the Petri dish. After that, 30 larvae of second-instar S. frugiperda and M. separata were transferred into the Petri dish and cultivated in the incubator at 27 ± 1°C for 48 h. Three replicates were performed for each treatment. The mortality rates were determined using Abbott’s formula.


## 3. Results and Discussion

### 3.1. Chemistry

The synthetic route for the target compounds is summarized in Scheme1. Firstly, using ethyl trifluoroacetoacetate, formamidine hydrochloride, and acetamidine hydrochloride as raw materials, 2-substituted-4-chloro-6-(trifluoromethyl)pyrimidine (2) was synthesized including cyclization and chlorination reactions. Next, the key intermediate 2-substituted-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid (3) was synthesized from 2-substituted-4-chloro-6-(trifluoromethyl)pyrimidine (2) reacting with 4-hydroxybenzoic acid and cesium carbonate in acetone under reflux conditions. Finally, the target compounds 4a–4q were obtained from 2-substituted-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid (3) and aromatic amines by amidation reaction.Scheme 1
Synthetic route for the target compounds4a–4q.


### 3.2. Antifungal Activity Test in Vitro

Table1 showed that compounds 4a, 4j, 4o, and 4q exhibited higher antifungal activity against B. dothidea, with the inhibition rates of 89.8%, 85.9%, 93.1%, and 98.5%, respectively, which were even better than pyrimethanil (84.4%). Meanwhile, compounds 4o and 4q exhibited higher antifungal activity against Phomopsis sp., with the inhibition rates of 89.0% and 92.0%, respectively, which were even better than pyrimethanil (85.1%). Furthermore, compounds 4a, 4f, 4g, 4o, 4p, and 4q revealed excellent antifungal activity against B. cinerea, with the inhibition rates of 90.3%, 91.7%, 86.8%, 96.7%, 83.8%, and 98.5%, respectively, which were even better than pyrimethanil (82.8%). Especially, compound 4q revealed the best antifungal activity against B. dothidea (98.5%), Phomopsis sp. (92.0%), and B. cinerea (98.5%) than those of pyrimethanil and the other target compounds.Table 1
Thein vitro antifungal activities against Phomopsis sp., B. dothidea, and B. cinerea of the target compounds 4a–4q at 50 µg/mL.
CompoundsInhibition rate (%)B. dothideaPhomopsis sp.B. cinerea4a90.8 ± 1.163.4 ± 2.193.3 ± 1.24b79.2 ± 1.257.0 ± 1.383.6 ± 1.44c67.5 ± 1.150.5 ± 1.872.0 ± 1.04d64.5 ± 1.960.2 ± 2.166.6 ± 1.24e24.6 ± 1.546.0 ± 1.456.8 ± 1.44f94.3 ± 1.480.6 ± 2.091.7 ± 2.34g76.8 ± 1.179.1 ± 1.286.8 ± 1.74h46.5 ± 2.356.1 ± 2.155.2 ± 2.64i32.1 ± 2.434.4 ± 1.139.6 ± 1.14j85.9 ± 1.961.0 ± 2.181.3 ± 3.24k70.9 ± 1.251.2 ± 1.875.2 ± 1.84l62.9 ± 2.545.1 ± 2.266.8 ± 2.34m53.5 ± 1.556.2 ± 1.156.0 ± 1.84n43.4 ± 1.846.1 ± 2.153.8 ± 1.24o93.5 ± 1.389.0 ± 1.096.7 ± 2.24p70.8 ± 1.172.1 ± 1.283.8 ± 1.04q98.5 ± 1.392.0 ± 1.097.6 ± 2.2Pyrimethanil84.4 ± 2.185.1 ± 1.482.8 ± 1.4According to the antifungal activity data, the difference ofR1 and R2 substituent groups was related to the antifungal activity of the target compounds. When the R2 was the same group, with the presence of -H at R1, the target compound revealed higher antifungal activity than compound with the R1 was -CH3. When R1 was H, compounds with the presence of -F and -OCF3 at R2 represented higher antifungal activity compared with the other target compounds.


### 3.3. Insecticidal Activity Test

Table2 shows that the target compounds 4a–4p indicated lower insecticidal activities against S. frugiperda (10.0–86.7%) and M. separata (13.3–90.0%) at 500 µg/mL than those of chlorantraniliprole. Especially, compound 4h demonstrated an excellent mortality rate of 90.0% against M. separata as well as compounds 4o and 4q revealed moderate insecticidal activity against S. frugiperda with the mortality rates of 83.3% and 86.7%, respectively.Table 2
The insecticidal activities againstS. frugiperda and M. separata of the target compounds 4a–4q at 500 µg/mL.
CompoundsMortality rate (%)S. frugiperdaM. separata4a20.0 ± 1.613.3 ± 1.04b30.0 ± 1.026.7 ± 1.24c33.3 ± 1.536.7 ± 2.24d23.3 ± 2.016.7 ± 2.04e10.0 ± 1.513.3 ± 1.34f53.3 ± 2.856.7 ± 1.24g46.7 ± 2.050.0 ± 1.04h73.3 ± 2.290.0 ± 1.54i30.0 ± 1.253.3 ± 1.24j26.7 ± 1.520.0 ± 1.84k40.0 ± 2.433.3 ± 2.04l43.3 ± 1.536.7 ± 2.24m26.7 ± 2.020.0 ± 2.44n16.7 ± 1.223.3 ± 1.84o83.3 ± 1.660.0 ± 2.34p40.0 ± 1.363.3 ± 1.54q86.7 ± 1.880.0 ± 2.4Chlorantraniliprole100100


## 3.1. Chemistry

The synthetic route for the target compounds is summarized in Scheme1. Firstly, using ethyl trifluoroacetoacetate, formamidine hydrochloride, and acetamidine hydrochloride as raw materials, 2-substituted-4-chloro-6-(trifluoromethyl)pyrimidine (2) was synthesized including cyclization and chlorination reactions. Next, the key intermediate 2-substituted-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid (3) was synthesized from 2-substituted-4-chloro-6-(trifluoromethyl)pyrimidine (2) reacting with 4-hydroxybenzoic acid and cesium carbonate in acetone under reflux conditions. Finally, the target compounds 4a–4q were obtained from 2-substituted-4-((6-(trifluoromethyl)pyrimidin-4-yl)oxy)benzoic acid (3) and aromatic amines by amidation reaction.Scheme 1
Synthetic route for the target compounds4a–4q.


## 3.2. Antifungal Activity Test in Vitro

Table1 showed that compounds 4a, 4j, 4o, and 4q exhibited higher antifungal activity against B. dothidea, with the inhibition rates of 89.8%, 85.9%, 93.1%, and 98.5%, respectively, which were even better than pyrimethanil (84.4%). Meanwhile, compounds 4o and 4q exhibited higher antifungal activity against Phomopsis sp., with the inhibition rates of 89.0% and 92.0%, respectively, which were even better than pyrimethanil (85.1%). Furthermore, compounds 4a, 4f, 4g, 4o, 4p, and 4q revealed excellent antifungal activity against B. cinerea, with the inhibition rates of 90.3%, 91.7%, 86.8%, 96.7%, 83.8%, and 98.5%, respectively, which were even better than pyrimethanil (82.8%). Especially, compound 4q revealed the best antifungal activity against B. dothidea (98.5%), Phomopsis sp. (92.0%), and B. cinerea (98.5%) than those of pyrimethanil and the other target compounds.Table 1
Thein vitro antifungal activities against Phomopsis sp., B. dothidea, and B. cinerea of the target compounds 4a–4q at 50 µg/mL.
CompoundsInhibition rate (%)B. dothideaPhomopsis sp.B. cinerea4a90.8 ± 1.163.4 ± 2.193.3 ± 1.24b79.2 ± 1.257.0 ± 1.383.6 ± 1.44c67.5 ± 1.150.5 ± 1.872.0 ± 1.04d64.5 ± 1.960.2 ± 2.166.6 ± 1.24e24.6 ± 1.546.0 ± 1.456.8 ± 1.44f94.3 ± 1.480.6 ± 2.091.7 ± 2.34g76.8 ± 1.179.1 ± 1.286.8 ± 1.74h46.5 ± 2.356.1 ± 2.155.2 ± 2.64i32.1 ± 2.434.4 ± 1.139.6 ± 1.14j85.9 ± 1.961.0 ± 2.181.3 ± 3.24k70.9 ± 1.251.2 ± 1.875.2 ± 1.84l62.9 ± 2.545.1 ± 2.266.8 ± 2.34m53.5 ± 1.556.2 ± 1.156.0 ± 1.84n43.4 ± 1.846.1 ± 2.153.8 ± 1.24o93.5 ± 1.389.0 ± 1.096.7 ± 2.24p70.8 ± 1.172.1 ± 1.283.8 ± 1.04q98.5 ± 1.392.0 ± 1.097.6 ± 2.2Pyrimethanil84.4 ± 2.185.1 ± 1.482.8 ± 1.4According to the antifungal activity data, the difference ofR1 and R2 substituent groups was related to the antifungal activity of the target compounds. When the R2 was the same group, with the presence of -H at R1, the target compound revealed higher antifungal activity than compound with the R1 was -CH3. When R1 was H, compounds with the presence of -F and -OCF3 at R2 represented higher antifungal activity compared with the other target compounds.


## 3.3. Insecticidal Activity Test

Table2 shows that the target compounds 4a–4p indicated lower insecticidal activities against S. frugiperda (10.0–86.7%) and M. separata (13.3–90.0%) at 500 µg/mL than those of chlorantraniliprole. Especially, compound 4h demonstrated an excellent mortality rate of 90.0% against M. separata as well as compounds 4o and 4q revealed moderate insecticidal activity against S. frugiperda with the mortality rates of 83.3% and 86.7%, respectively.Table 2
The insecticidal activities againstS. frugiperda and M. separata of the target compounds 4a–4q at 500 µg/mL.
CompoundsMortality rate (%)S. frugiperdaM. separata4a20.0 ± 1.613.3 ± 1.04b30.0 ± 1.026.7 ± 1.24c33.3 ± 1.536.7 ± 2.24d23.3 ± 2.016.7 ± 2.04e10.0 ± 1.513.3 ± 1.34f53.3 ± 2.856.7 ± 1.24g46.7 ± 2.050.0 ± 1.04h73.3 ± 2.290.0 ± 1.54i30.0 ± 1.253.3 ± 1.24j26.7 ± 1.520.0 ± 1.84k40.0 ± 2.433.3 ± 2.04l43.3 ± 1.536.7 ± 2.24m26.7 ± 2.020.0 ± 2.44n16.7 ± 1.223.3 ± 1.84o83.3 ± 1.660.0 ± 2.34p40.0 ± 1.363.3 ± 1.54q86.7 ± 1.880.0 ± 2.4Chlorantraniliprole100100


## 4. Conclusion

In summary, 17 novelN-phenylbenzamide derivatives containing a trifluoromethylpyrimidine moiety were prepared, and their structures were confirmed by 1H NMR, 13C NMR, and HRMS. Biological activity results indicated that most of the target compounds exhibited moderate to good antifungal and insecticidal activities. Among them, compound 4q revealed the best antifungal activities against Phomopsis sp., B. dothidea, and B. cinerea than those of pyrimethanil and the other target compounds. This study provided hope for discovery, development, design, and synthesis of novel N-phenylbenzamide derivatives containing a trifluoromethylpyrimidine.



---

*Source: 8370407-2021-09-16.xml*